SipNose-topiramate: a potential novel approach to binge eating management.

ABSTRACT:

Background

Binge-eating disorder) BED) is the most common eating disorder in the United-States. Daily, orally administered topiramate has shown BED treatment efficacy, with two major limitations: frequent and severe side effects and slow time-to-effect. SipNose is a novel non-invasive intranasal direct nose-to-brain drug delivery platform that delivers drugs to the central nervous system consistently and rapidly. Herein, we study a SipNose-topiramate combination product, as an acute "as needed" (PRN) solution for BED management.

Methods

First, SipNose-topiramate's pharmacokinetics (PK) and safety was evaluated. The second part aimed to demonstrate its PRN-treatment feasibility in terms of usability and potential efficacy in reducing the number of binge-eating events. Twelve

SUBMITTER: Kobo-Greenhut A 

PROVIDER: S-EPMC10294342 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature